Infiltration of Medical Ozone for the Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ)

MEDICATION RELATED OSTEONECROSIS OF THE JAW Clinical Trial

— OZOPROMAF  

Official title:

OZOPROMAF: Validation Study of the Use of Ozonotherapy in Mronj Management- Protocol of Ozone by Infiltrations in Patients With Osteonecrosis of the Jaws Drug Related

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05036837
• Other study ID #: OZOPROMAF_SEQ1
• Status: Suspended
• Phase: Phase 1/Phase 2
• Start date: February 1, 2018
• Est. completion date: March 1, 2022

Study information

• Verified date: September 2021
• Source: University of Palermo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is also a potentially painful and debilitating condition. Today, no specific studies have prospectively evaluated the efficacy of its treatment and no robust standard of care has been established.

Among non-invasive procedures to treat MRONJ, the use of medical ozone (O3) arises for its properties and has been deployed and evaluated. O3 has generally proven to play a role in the treatment of chronic, nonhealing, or ischemic wounds, due to its antimicrobial and anti-oxidant properties and to bio-stimulation; it has been extensively used for different medical approaches and purposes. In oral cavity, local applications are carried out by ozonized water (i.e. spray or compress) or gel.

The aim of this open trial is to assess the efficacy and the safety of O3 by a new method of application, i.e. infiltrations of oral mucosa, in patients with a diagnosis of MRONJ, which are non-eligible for the standard of care, regardless staging.

All cases included in our study are MRONJ and staged according to the classification of the Italian Societies of Oral Medicine and Maxillofacial Surgery (the SICMF/SIPMO staging system); in addition, they arereported to AIFA, the Italian Medicines Agency, for registration of the adverse event drug related.Patients included in our study are selected due to their non-eligibility to the standard treatment (conservative/medical for long term or surgical alone) for unstable systemic conditions or unaccepted consent due to extensive proposed approach due to the advanced disease.

During the first examination (T0), medical, pharmacological, and dental history of patients are recorded. Data collected are: (1) age; (2) gender; (3) indications for use, type, cumulative dose and duration of MRONJ-related drugs; (4); history of chemotherapy; (5) other medications; (6) other diseases; (7) smoking.

For every patient, Cone Beam CT dental scan or maxillofacial CT scan has performed for staging at T0 and 12 (T4) months after; orthopantomograph has performed during protocol (T3). The main CT features evaluated and associated to MRONJ presence and healing are as follows: a) bone sclerosis, b) depth of lesion; c) formation of sequestrum.

When more than one MRONJ lesion are present, the protocol is applied one by one.

Description:

OZOPROMAF protocol consists of: local superficial anesthesia by application of EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (O2O3) mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan.

Moreover, pain intensity is assessed at each visit by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).

OZOPROMAF is applied on 7-15 days, depending on the patient compliance, until the resolution, identified as formation of sequestrum and clinical healing (T1).

The day after the procedure, every patient iss supported by phone evaluating pain and/or adverse events with a questionnaire In case of unavailability of the patient for the weekly treatment, it is mandatory the phone call for the questionnaire, in order to evaluate symptoms by simple questions and NAS scale.

After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3 and T4.

Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 50
• Est. completion date: March 1, 2022
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Clinical and radiological diagnosis of MRONJ

• Patients with MRONJ non-eligibilible to the standard treatment (medical or surgical alone) for unstable systemic conditions or for unaccepted consent due.

Exclusion Criteria:

• Head and neck radiotherapy

• Long term sistemic antimicrobial therapy

Related Conditions & MeSH terms

• MEDICATION RELATED OSTEONECROSIS OF THE JAW
• Osteonecrosis

Intervention

Drug:
• OZOPROMAF_SEQ1
OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1/2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1). Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS). After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3 and T4. Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera Universitaria Policlinico "P. Giaccone" Palermo - University of Palermo	Palermo	Italy - Sicily

Sponsors (1)

Lead Sponsor	Collaborator
University of Palermo

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MUCOSAL HEALING	no clinical signs and no symptoms compatible with MRONJ outcome measure: formation of sequestrum by visualization of bone sequestrum; no infectius signs by visual inspection; no pain by NAS	3 months
Primary	MUCOSAL HEALING (1-T2)	no clinical signs Outcome measure: no clinical signs compatible with MRONJ by visual inspection	3 months (T2)
Primary	MUCOSAL HEALING (2-T2)	no symptoms Outcome measure: pain evaluation by NAS	3 months (T2)
Primary	BONE HEALING (T2)	Outcome measure: no radiological signs compatible with MRONJ by OPT (orthopantomograph)	3 months (T2)
Primary	MUCOSAL HEALING (1-T3)	no clinical signs Outcome measure: no clinical signs compatible with MRONJ by visual inspection	6 months (T3)
Primary	MUCOSAL HEALING (2-T3)	no symptoms Outcome measure:pain evaluation by NAS	6 months (T3)
Primary	BONE HEALING (T3)	Outcome measure: no radiological signs compatible with MRONJ by CT (computed tomography)	6 months (T3)
Primary	MUCOSAL HEALING (1-T4)	no clinical signs Outcome measure: no clinical signs compatible with MRONJ by visual inspection	12 months (T4)
Primary	MUCOSAL HEALING (2-T4)	no symptoms Outcome measure:pain evaluation by NAS	12 months (T4)
Primary	BONE HEALING (T4)	Outcome measure: no radiological signs compatible with MRONJ by CT (computed tomography)	12 months (T4)
Primary	MUCOSAL HEALING (1-T5)	no clinical signs Outcome measure: no clinical signs compatible with MRONJ by visual inspection	18-24 months (T5)
Primary	MUCOSAL HEALING (2-T5)	no symptoms Outcome measure: pain evaluation by NAS	18-24 months (T5)
Primary	BONE HEALING (T5)	Outcome measure: no radiological signs compatible with MRONJ by CT (computed tomography)	18-24 months (T5)

External Links

•   Related Info